Check Our Sources
In Moderna’s study, 9.7% of trial participants were African American, 20% of them Hispanic/Latino, 4.7% of them Asian, and 5.2%, and < 3% from other racial groups. 36.5% communities of color. In Pfizer’s study, 9.8% of trial participants were African American, 26.2% of them Hispanic, 4.4% of them Asian, and < 3% from other racial groups. Find further vaccine trial demographics in the FDA reports for Moderna and Pfizer.
Because of institutionalized racism’s impact on healthcare access and other general socioeconomic constraints, Black, Hispanic, Asian, Native American and other racial and ethnic minorities have been consistently underrepresented in clinical trials. The COVID pandemic has impacted these groups disproportionately and raised awareness—and created a sense of urgency—about the need to include them in clinical trials. This context made vaccine developers focus on recruiting representative population samples for their studies in order to make sure the vaccine would work for everyone. Both Pfizer and Moderna achieved sample populations that reflected the adult United States’ population demographics. Over a third of vaccine participants were People of Color; 10% of them Black and 20% of them Hispanic.
To request more information about COVID-19 and FLU vaccines, please fill out this form.
By submitting this form, you agree to receive text messages for purposes related to vaccine information only. Message and data rates may apply.